Oligonucleotide inhibitors of telomerase: Prospects for anticancer therapy and diagnostics
详细信息 查看全文
- 作者：M. I. Zvereva ; T. S. Zatsepin ; D. M. Azhibek ; O. S. Shubernetskaya…
- 关键词：human telomerase ; telomerase inhibitors ; anticancer therapy target ; oligonucleotide ; tumor cell imaging
- 刊名：Biochemistry (Moscow)
- 出版年：2015
- 出版时间：March 2015
- 年：2015
- 卷：80
- 期：3
- 页码：251-259
- 全文大小：334 KB
- 参考文献：1. Zvereva, M I, Shcherbakova, D M, Dontsova, O A (2010) Telomerase: structure, functions, and activity regulation. Biochemistry (Moscow) 75: pp. 1563-1583 CrossRef
2. Blagoev, K B (2009) Cell proliferation in the presence of telomerase. PLoS One 4: pp. e4622 CrossRef
3. Hamad, N M, Banik, S S, Counter, C M (2002) Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene 21: pp. 7121-7125 CrossRef
4. Ale-Agha, N, Dyballa-Rukes, N, Jakob, S, Altschmied, J, Haendeler, J (2014) Cellular functions of the dual-targeted catalytic subunit of telomerase, telomerase reverse transcriptase -potential role in senescence and aging. Exp. Gerontol. 56: pp. 189-193 CrossRef
5. Bernardes de Jesus, B, Blasco, M A (2013) Telomerase at the intersection of cancer and aging. Trends Genet. 29: pp. 513-520 CrossRef
6. Bernardes de Jesus, B, Schneeberger, K, Vera, E, Tejera, A, Harley, C B, Blasco, M A (2011) The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell 10: pp. 604-621 CrossRef
7. Hodes, R (2001) Molecular targeting of cancer: telomeres as targets. Proc. Natl. Acad. Sci. USA 98: pp. 7649-7651 CrossRef
8. Ruden, M, Puri, N (2013) Novel anticancer therapeutics targeting telomerase. Cancer Treat. Rev. 39: pp. 444-456 CrossRef
9. Chen, H, Li, Y, Tollefsbol, T O (2009) Strategies targeting telomerase inhibition. Mol. Biotechnol. 41: pp. 194-199 CrossRef
10. Sedlak, R H, Jerome, K R (2013) Viral diagnostics in the era of digital polymerase chain reaction. Diagn. Microbiol. Infect. Dis. 75: pp. 1-4 CrossRef
11. Zhou, Y, Zhu, S, Cai, C, Yuan, P, Li, C, Huang, Y, Wei, W (2014) High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509: pp. 487-491 CrossRef
12. Martinez, T, Wright, N, Lopez-Fraga, M, Jimenez, A I, Paneda, C (2013) Silencing human genetic diseases with oligonucleotide-based therapies. Hum. Genet. 132: pp. 481-493 CrossRef
13. Dassie, J P, Giangrande, P H (2013) Current progress on aptamer-targeted oligonucleotide therapeutics. Ther. Deliv. 4: pp. 1527-1546 CrossRef
14. Burnett, J C, Rossi, J J (2012) RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19: pp. 60-71 CrossRef
15. Malik, R, Roy, I (2011) Making sense of therapeutics using antisense technology. Expert Opin. Drug Discov. 6: pp. 507-526 CrossRef
16. Dirin, M, Winkler, J (2013) Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opin. Biol. Ther. 13: pp. 875-888 CrossRef
17. Juliano, R L, Carver, K, Cao, C, Ming, X (2013) Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonu-cleotides. J. Drug Target 21: pp. 27-43
文摘
The activity of telomerase allows eukaryotic cells to have unlimited division potential. On its functioning, telomerase synthesizes short DNA repeats at the 3-end of DNA within chromosomes that ensures genome stability during cell division. Telomerase is active in the majority of cancer cell types and is virtually absent in somatic cells with rare exceptions. This difference allows us to consider inhibition of telomerase activity as a possible approach to antitumor therapy. Telomerase is a nucleoprotein composed of two main components: the reverse transcriptase (hTERT), which is a catalytic subunit, and telomerase RNA (hTR), which encodes a template for synthesis of repeats. The biogenesis and features of telomerase seem very promising for its inhibition due to complementary interactions. In this review, we analyze putative pathways of oligonucleotide influence on telomerase and consider the known native and modified oligonucleotide inhibitors of telomerase, as well as possible mechanisms of their action. We also discuss the application of telomerase-targeted oligonucleotide conjugates for in vivo imaging of tumor cells.